Transforming the gene therapy landscape
with AI-powered AAV vectors

The Outlook

Gene therapies of the future will be designed using artificial intelligence (AI) to reach more patients and treat many more diseases.

Our Solution

Dyno Therapeutics is applying AI technology to discover novel gene therapy vectors with transformative delivery properties for a vast landscape of human diseases.


Read about our scientists' publications in Science, Nature Biotechnology, at ASGCT and more.


Dyno closes $100 million Series A financing led by Andreessen Horowitz


Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence

Back to Top